e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Biomarkers in sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of discriminant analysis to assess pulmonary functional worsening in patients with sarcoidosis by means of a panel of inflammatory markers
G. Paone, M. Rulli, A. Belli, A. Propati, A. Sbrocca, S. D‘Antonio, A. Sebastiani, G. Puglisi, G. Galluccio, S. Batzella (Rome, Milan, Italy)
Source:
Annual Congress 2011 - Biomarkers in sarcoidosis
Session:
Biomarkers in sarcoidosis
Session type:
Oral Presentation
Number:
4520
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Paone, M. Rulli, A. Belli, A. Propati, A. Sbrocca, S. D‘Antonio, A. Sebastiani, G. Puglisi, G. Galluccio, S. Batzella (Rome, Milan, Italy). Use of discriminant analysis to assess pulmonary functional worsening in patients with sarcoidosis by means of a panel of inflammatory markers. Eur Respir J 2011; 38: Suppl. 55, 4520
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Relationships between COPD assessment test score and pulmonary function tests or quantitative CT analysis in Japanese COPD patients
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013
Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011
Gene-set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis
Source: Annual Congress 2010 - Sarcoidosis: genes and mechanisms
Year: 2010
Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 258s
Year: 2002
Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020
Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD
Source: Annual Congress 2008 - Structural remodelling in COPD
Year: 2008
A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00096-2016; 10.1183/23120541.00096-2016
Year: 2017
Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Hierarchy of common lung function parameters in diagnosing COPD using discriminant analysis
Source: Annual Congress 2010 - New diagnostic approaches in respiratory function
Year: 2010
Association of texture-based quantitative fibrotic patterns and pulmonary function test in a new validation set
Source: Annual Congress 2011 - Functional lung and pulmonary arterial imaging
Year: 2011
Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 6 (4) 00347-2020; 10.1183/23120541.00347-2020
Year: 2020
18
FDG-PET imaging detects inflammatory changes in pediatric cystic fibrosis patients after treatment for a pulmonary exacerbation
Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections
Year: 2010
Comparative analysis of routine biochemistry data and neurohormonal markers in patients with different forms of pulmonary hypertension
Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases
Year: 2010
Inflammatory markers in cystic fibrosis patients with different values of pulmonary function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 528s
Year: 2002
Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
The use of FENO in COPD: the relationship to pulmonary function tests and its importance in differential diagnosis.
Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Year: 2017
Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
Source: Eur Respir J 2014; 44: 951-962
Year: 2014
Comparative evaluation of diagnosis methods in the patients with pulmonary sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 539s
Year: 2006
Correlation of different thresholds in CT lung densitometry and pulmonary function tests in stable COPD patients
Source: Annual Congress 2007 - Imaging modalities in asthma, COPD and emphysema
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept